UK's TSB provides £347,000 for project to optimise gene library assembly technology

NewsGuard 100/100 Score

Today, Monday 30th June, 2014, Isogenica, Cambridge UK and Imperial College London secure funding from the Technology Strategy Board (TSB), the UK's innovation agency, for a £347,000 project to optimise a gene library assembly technology for potential use in synthetic biology.

This support from the TSB follows the successful development by Isogenica of its Colibra™ technology for the commercial synthesis of ratio controlled gene libraries using a patent protected methodology discovered by Dr Anna Hine of Aston University which was also supported by TSB funding.

Isogenica will now work with Dr. Geoff Baldwin at Imperial College London to take advantage of their 'BASIC' DNA assembly technology. This will allow both parties to efficiently optimise the assembly of genes from smaller DNA fragments and generate combinatorial libraries of genetic mutations for application in the field of synthetic biology.

"Isogenica is currently commercialising the Colibra™ technology for ratio controlled protein and antibody libraries based on a partly automated process. We are now interested in further optimising the technology for high throughput, automated manufacture of whole gene libraries and we believe that this could represent a powerful and valuable tool for commercialisation in the synthetic biology arena" said Kevin Mathews, CEO of Isogenica.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rare variants in the YKT6 gene cause new neurological disorder, study finds